Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 28, 2014; 20(48): 18070-18091
Published online Dec 28, 2014. doi: 10.3748/wjg.v20.i48.18070
Table 1 Studies and their findings on adiponectin
HumanAdiponectin levels reduced in obese individuals[25,34,35]
Adiponectin levels higher in women[36]
Adiponectin levels reduced in T2DMHypoadiponectinemia associated with visceral fat accumulation[37]
High concentrations of adiponectin correlated with a decreased risk of developing T2DM[41-43]
Adiponectin mRNA decreased in obese T2DM[40]
SNP +45T>G genotypes and lower adiponectin level associated with higher FBG, insulin levels and HOMA-IR in obese women[48]
SNPs: 3971 A/G (rs822396), +276 G/T (rs1501299), -4522 C/T (rs822393) and Y111H T/C (rs17366743) significantly associated with hypoadiponectinemia[49]
High adiponectin/leptin ratio associated with lower plasma triglyceride, HOMA-IR and higher HDL[44]
Lower adiponectin levels an independent risk factor for NAFLD[51]
In human liver biopsies, hepatic adiponectin receptor mRNAs increased in biopsy-proven NASH[52]
Similar levels of adiponectin receptor mRNA in normal, steatotic liver and NASH[53,54]
Reduced AdipoR2 protein in NASH compared to steatotic liver[55]
Adiponectin levels lower in NASH and correlated with the progression of the disease[56,70-72]
HMW adiponectin isoforms increased after biliopancreatic diversion in obese subjects[77]
AnimalAdiponectin lowers gluconeogenesis in the liver, increases fatty acid oxidation in muscle and reduces IR[45]
Disruption of both adiponectin receptors (adipo R1 and R2) increased tissue triglyceride content, inflammation, oxidative stress and IR[46]
Adiponectin enhanced the progression of hepatic steatosis, fibrosis, and hepatic tumor formation in NASH[57]
Adiponectin prevents lipid accumulation by increasing β-oxydation and by decreasing synthesis of FFA in hepatocytes in NASH[47,58-60]
Association of NAFLD and reduced expression of hepatic adiponectin receptors not consistently reported[61,62]
Peripheral injection of adiponectin resulted in reduction in body weight and improvement of peripheral IR[47]
Adiponectin reduced TNF-α and induced IL-10 release from Kupffer cells[63]
Pretreatment with adiponectin ameliorated D-galactosamine/LPS induced elevation of serum AST and ALT levels, and the apoptotic and necrotic changes in hepatocytes[64]
In vitroAdiponectin inhibited TNF-α induced expression of endothelial adhesion molecules and decreased LPS induced TNF-α production[66]
Adiponectin mediated anti-inflammatory activity by lowering NFκB action[67]
Adiponectin increased IL-8 and monocyte chemotactic protein-1 production, and activated the proinflammatory transcription factor NFκB[68]
Adiponectin acted antifibrotic through antagonizing leptin-induced STAT3 phosphorylation in activated hepatic stellate cell who promote fibrosis[73]
Lower HMW adiponectin closely associated with obesity-related metabolic complications and T2DM[75]